Home › Funds › BAKER BROS. ADVISORS LP › ABCL

BAKER BROS. ADVISORS LP position in ABCL

ABCELLERA BIOLOGICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 33,012,138 shares of ABCL (ABCELLERA BIOLOGICS INC) in its Q2 2026 13F filing — a position valued at US$259.1M, representing 1.35% of its reported portfolio and ranking #14 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed ABCL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)33.01M sh
Reported value held$259.15M
Portfolio Weight1.35%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's ABCL position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in ABCL in Q3 2023 at 20,763,323 shares (US$95.5M). The position peaked in Q2 2026 at 33,012,138 shares, worth US$259.1M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 33,012,138 shares valued at US$259.1M — an increase of 2,736,200 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 20.76M $95.51M New
Q4 2023 22.91M $130.81M Add
Q1 2024 27.53M $124.69M Add
Q2 2024 27.53M $81.48M Hold
Q3 2024 27.53M $71.57M Hold
Q4 2024 27.53M $80.65M Hold
Q1 2025 27.53M $61.38M Hold
Q2 2025 27.53M $94.41M Hold
Q3 2025 27.53M $138.45M Hold
Q4 2025 27.53M $94.14M Hold
Q1 2026 30.28M $105.66M Add
Q2 2026 33.01M $259.15M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABCL and 13F data

ABCL (ABCELLERA BIOLOGICS INC) is a Health Care company. 37 other funds we track also report a position in ABCL — the largest reported positions include ArrowMark Colorado Holdings LLC (US$32.2M), Guardian Partners Inc. (US$8.7M), Intellectus Partners, LLC (US$4.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABCL

All ABCL fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held ABCL?

BAKER BROS. ADVISORS LP has disclosed ABCL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in ABCL?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 33.01M shares of ABCL (ABCELLERA BIOLOGICS INC), valued at $259.15M, representing 1.35% of its reported portfolio and ranking #14.

Has BAKER BROS. ADVISORS LP been buying or selling ABCL?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in ABCL. The position peaked in Q2 2026 at 33.01M shares.

Which other funds hold ABCL?

Other major institutional holders of ABCL include ArrowMark Colorado Holdings LLC, Guardian Partners Inc., Intellectus Partners, LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.